# US 2024/0174719 A1 · Proteins and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0174719 A1
- Document ID: US20240174719A1
- Status: Published application
- Kind: A1
- Application number: 18/550,807
- Filed: 2022-03-17
- Published: 2024-05-30
- Earliest claimed: 2021-03-17
- Assignees: James Cook University
- Applicants: James Cook University
- Inventors: Alexander Constantine Loukas; Paul Robert Giacomin; Stephanie Margaret Ryan; Roland Ruscher
- Web page: https://patentgrep.com/patent/US20240174719A1

## CPC

- A61P 1/06: Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- C07K 14/001: {by chemical synthesis}
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 14/44: from protozoa
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to proteins suitable for treating or preventing an inflammatory or autoimmune condition, pharmaceutical compositions comprising same, and methods of use comprising same.

## Claims

### Claim 1

An isolated, recombinant or synthetic protein comprising an amino acid sequence having at least about 70% sequence identity to any one of SEQ ID NOs:4, 8, 11, 1, 6, 2, 3, 5, 7, 9, 10, 12, 13, 14, 15, 16, 17, 18, 19 and 20, preferably any one of SEQ ID NOs: 4, 8, 11, 1 and 6, more preferably any one of SEQ ID NOs: 4, 8 and 11, or a biologically active fragment or variant thereof.

### Claim 2 (depends on 1)

The protein according to claim 1 wherein the amino acid sequence has at least about 80%, at least about 90%, at least about 95%, at least about 98%, or at least about 99% sequence identity to any one of SEQ ID NOs:1-20, preferably any one of SEQ ID NOs: 4, 8, 11, 1 and 6, more preferably any one of SEQ ID NOs: 4, 8 and 11.

### Claim 3 (depends on 1, 2)

The protein according to claim 1 or claim 2 wherein the amino acid sequence is any one of SEQ ID NOs:1-20, preferably any one of SEQ ID NOs: 4, 8, 11, 1 and 6, more preferably any one of SEQ ID NOs: 4, 8 and 11.

### Claim 4 (depends on 1, 2, 3)

The protein according to any one of claims 1 to 3 wherein the amino acid sequence has at least about 70% sequence identity to any one of SEQ ID NOs:4, 8, 1, 6, 2, 3, 5 and 7, preferably any one of SEQ ID NOs: 4, 8, 1 and 6, more preferably any one of SEQ IDs: 4 and 8.

### Claim 5 (depends on 1, 2, 3, 4)

The protein according to any one of claims 1 to 4 wherein the amino acid sequence has at least about 80%, at least about 90%, at least about 95%, at least about 98%, or at least about 99% sequence identity to any one of SEQ ID NOs:1-8, preferably any one of SEQ ID NOs: 4, 8, 1 and 6, more preferably any one of SEQ IDs: 4 and 8.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The protein according to any one of claims 1 to 5 wherein the amino acid sequence is any one of SEQ ID NOs:1-8, preferably any one of SEQ ID NOs: 4, 8, 1 and 6, more preferably any one of SEQ IDs: 4 and 8.

### Claim 7

An isolated, recombinant or synthetic protein comprising an amino acid sequence in which a total of up to about 250 amino acids have been substituted, inserted and/or deleted in any one of SEQ ID NOs:4, 8, 11, 1, 6, 2, 3, 5, 7, 9, 10, 12, 13, 14, 15, 16, 17, 18, 19 and 20, preferably any one of SEQ ID NOs: 4, 8, 11, 1 and 6, more preferably any one of SEQ ID NOs: 4, 8 and 11, or a biologically active fragment or variant thereof.

### Claim 8 (depends on 7)

The protein according to claim 7 in which a total of up to about 225, up to about 200, up to about 175, up to about 125, up to about 100, up to about 75, up to about 50, up to about 40, up to about 30, up to about 25, up to about 20, up to about 15 or up to about 10 amino acids have been substituted, inserted and/or deleted in any one of SEQ ID NOs:1-20, preferably any one of SEQ ID NOs: 4, 8, 11, 1 and 6, more preferably any one of SEQ ID NOs: 4, 8 and 1.

### Claim 9 (depends on 7, 8)

The protein according to claim 7 or claim 8 wherein the amino acid sequence has a total of up to about 250 amino acids which have been substituted, inserted and/or deleted in any one of SEQ ID NOs:1-8, or a biologically active fragment or variant thereof.

### Claim 10 (depends on 7)

The protein according to claim 7 wherein the amino acid sequence has a total of up to about 225, up to about 200, up to about 175, up to about 125, up to about 100, up to about 75, up to about 50, up to about 40, up to about 30, up to about 25, up to about 20, up to about 15 or up to about 10 amino acids which have been substituted, inserted and/or deleted in any one of SEQ ID NOs:4, 8, 1, 6, 2, 3, 5 and 7, preferably any one of SEQ ID NOs: 4, 8, 11, 1 and 6, more preferably any one of SEQ IDs: 4 and 8.

### Claim 11

A recombinant protein encoded by a nucleotide sequence having at least about 70% sequence identity with any one of SEQ ID NOs:24, 28, 31, 21, 26, 43, 46, 48, 41, 45, 22, 23, 25, 27, 29, 30, 32, 33, 34, 35, 36, 37, 38, 39, 40, 42, 43, 44, 47, 49, 50, 51, 52 and 53, preferably any one of SEQ ID NOs:24, 28, 31, 21 and 26, more preferably any one of SEQ ID NOs: 24, 28 and 31, or a biologically active fragment or variant thereof.

### Claim 12 (depends on 11)

The protein according to claim 11 wherein the nucleotide sequence has at least about 80%, at least about 90%, at least about 95%, at least about 98%, or at least about 99% sequence identity to any one of SEQ ID NOs:21-53, preferably any one of SEQ ID NOs:24, 28, 31, 21 and 26, more preferably any one of SEQ ID NOs: 24, 28 and 31.

### Claim 13 (depends on 11, 12)

The protein according to claim 11 or claim 12 wherein the nucleotide sequence is any one of SEQ ID NOs:21-53, preferably any one of SEQ ID NOs:24, 28, 31, 21, 26, 43, 46, 48, 41 and 45, more preferably any one of SEQ ID NOs: 24, 28 and 31.

### Claim 14 (depends on 11, 12, 13)

The protein according to any one of claims 11 to 13 wherein the nucleotide sequence has at least about 70% sequence identity to any one of SEQ ID NOs:21-28, preferably any one of SEQ ID NOs:24 and 28.

### Claim 15 (depends on 11, 12, 13, 14)

The protein according to any one of claims 11 to 14 wherein the nucleotide sequence has at least about 80%, at least about 90%, at least about 95%, at least about 98%, or at least about 99% sequence identity to any one of SEQ ID NOs:21-28, preferably any one of SEQ ID NOs:24 and 28.

### Claim 16 (depends on 11, 12, 13, 14, 15)

The protein according to any one of claims 11 to 15 wherein the nucleotide sequence is any one of SEQ ID NOs:21-28, preferably any one of SEQ ID NOs:24 and 28.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A pharmaceutical composition comprising the protein according to any one of claims 1 to 16, or a biologically active fragment or variant thereof, and at least one pharmaceutically acceptable carrier.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

A method for treating or preventing an inflammatory or autoimmune condition comprising administering to a subject in need thereof the protein according to any one of claims 1 to 16, or a biologically active fragment or variant thereof, or the pharmaceutical composition according to claim 17, thereby treating or preventing an inflammatory or autoimmune condition in the subject.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

A method for the treatment or prevention of an inflammatory or autoimmune condition in a subject comprising the steps of:
identifying a subject having an inflammatory or autoimmune condition; and
administering to the subject in need thereof a therapeutically effective amount of the protein according to any one of claims 1 to 16, or a biologically active fragment or variant thereof, or the pharmaceutical composition according to claim 17
thereby treating or preventing an inflammatory or autoimmune condition in the subject

### Claim 20 (depends on 18, 19)

The method according to claim 18 or claim 19 wherein the inflammatory or autoimmune condition is selected from an inflammatory bowel disease, irritable bowel syndrome, type 2 diabetes, asthma, rheumatoid arthritis, lupus, allergy and coeliac disease.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

Use of the protein according to any one of claims 1 to 16, or a biologically active fragment or variant thereof, in the manufacture of a medicament for treating or preventing an inflammatory or autoimmune condition.

### Claim 22 (depends on 21)

The use of claim 21 wherein the inflammatory or autoimmune condition is selected from an inflammatory bowel disease, irritable bowel syndrome, type 2 diabetes, asthma, rheumatoid arthritis, lupus, allergy and coeliac disease.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The protein according to any one of claims 1 to 16, ora biologically active fragment or variant thereof, for use in treating or preventing an inflammatory or autoimmune condition.

### Claim 24 (depends on 23)

The protein according to claim 23 wherein the inflammatory or autoimmune condition is selected from an inflammatory bowel disease, irritable bowel syndrome, type 2 diabetes, asthma, rheumatoid arthritis, lupus, allergy and coeliac disease.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

An isolated nucleic acid comprising a nucleotide sequence encoding the protein according to any one of claims 1 to 16 or a biologically active fragment or variant thereof.

### Claim 26 (depends on 25)

A vector or expression construct comprising the nucleic acid according to claim 25.

### Claim 27 (depends on 25, 26)

A cell comprising the nucleic acid according to claim 25 or the vector or expression construct according to claim 26.

### Claim 28 (depends on 27)

A method of producing a protein or a biologically active fragment or variant thereof comprising incubating the cell of claim 27 under conditions that allow it to express the protein or biologically active fragment or variant thereof.
